ReportsnReports. com adds new research report Global Lifestyle Drugs Market 2017-2021. This report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021. To calculate the market size, the report considers sales of lifestyle drugs in the market.
Inquire for more information at http:// www. reportsnreports. com / contacts / inquirybeforebuy. aspx? name = 917357
The following companies are the key players in the global lifestyle drugs market: Allergan, BMS, Eli Lilly, and Pfizer.
Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma, Hanmi Pharmaceutical, Incyte, Intrepid Therapeutics, Ion Channel Innovations, iX Biopharma, Johnson & Johnson, Legacy Healthcare, LEO Pharma, H. Lundbeck, Luye America Pharmaceuticals, Merck, Minerva Neurosciences, MSI Methylation Sciences, Neuralstem, Novan, Novartis, Novo-Nordisk, Palatin Technologies, Paratek Pharmaceuticals, Photocure, Revance Therapeutics, Rhythm Pharmaceuticals, S1 Biopharma, Sage Therapeutics, Samumed, Sanofi, Sigma-Tau Pharmaceuticals, Strategic Science & Technologies, Sumitomo Dainippon Pharma, Takeda, TetraLogic Pharmaceuticals, TherapeuticsMD, Valeant Pharmaceuticals, VistaGen Therapeutics, VIVUS, XBiotech, Yuhan, and Zafgen.
One trend in the market is the increase in M & A. The market has been witnessing an increase in M & A, which will lead to further consolidation. The vendors are pursuing inorganic growth strategies such as acquisitions and / or partnerships to expand their lifestyle drugs portfolio and to improve their presence in the market. For instance, in August 2015, Allergan completed the acquisition of Naurex. The acquisition enhanced Allergan ' s portfolio of depression drugs with the addition of rapastinel, a Phase III-ready molecule that demonstrated rapid and sustained efficacy in multiple Phase II clinical studies in depression. With the patent expires in the market place, vendors are also looking to enhance their portfolio through acquisition of generics.
Purchase directly at http:// www. reportsnreports. com / purchase. aspx? name = 917357
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
According to the report, one driver in the market is the lifestyle changes. Lifestyle changes such as physical inactivity, stress, consumption of fast foods, and limited intake of water can lead to the development of acne. Research studies report that people who are physically inactive are prone to develop insulin resistance compared with active individuals. Insulin resistance leads to the production of higher levels of sebum in the skin, resulting in acne development. Research studies also put forth that excess insulin can increase the levels of androgens in the body. High levels of androgens also lead to an increased production of sebum in the skin, resulting in acne development.